The originator product, UCB’s Cimzia (certolizumab pegol), was approved by the US Food and Drug Administration (FDA) in April 2008 and by the European Medicines Agency (EMA) in October 2009 [1]. Cimzia had sales of US$1.1 billion in 2015.

The patents on Cimzia will expire in Europe in 2021 and in the US in 2024 [1]. Some of the certolizumab pegol biosimilars and non-originator biologicals* approved or in development are presented in Table 1.

Table 1: Biosimilars and non-originator biologicals* of certolizumab pegol in development

Editor’s comment
It should be noted that ‘non-originator biologicals’ approved in less regulated countries might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Related article
Biosimilars of palivizumab

Reference
1. Derbyshire M. Patent expiry dates for biologicals: 2016 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(1):27-30. doi:10.5639/gabij.2017.0601.006

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.